Indonesia Q2 GDP beats expectations with fastest growth in two years
A Reuters poll had expected growth of 4.80%. The second-quarter growth rate was the fastest since the second quarter of 2023, data from the statistics bureau showed.
On a non-seasonally adjusted, quarter-on-quarter basis, gross domestic product expanded 4.04% in April-June, Statistics Indonesia said.
Ahead of Tuesday's data, Bank Indonesia, which has cut policy rates four times since September, forecast economic growth would be in a range of 4.6% to 5.4% this year.
Manufacturing helped drive the stronger-than-expected growth, helped by demand for export goods such as palm oil products and base metals as well as domestic demand for pharmaceuticals.
Frontloading of export orders as buyers sought to get ahead of U.S. tariffs has seen the value of exports rise in the first half of the year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
28 minutes ago
- Reuters
European shares end flat as healthcare stocks weigh after Trump's tariff threat
Aug 6 (Reuters) - European shares closed flat on Wednesday, surrendering early session gains, as healthcare stocks felt the pinch from U.S. President Donald Trump's latest threat to impose higher tariffs on pharmaceutical imports. The pan-European STOXX 600 (.STOXX), opens new tab index closed 0.06% lower, breaking its two-day winning streak despite starting the session on a positive note. Healthcare stocks bore the brunt of the selling pressure. The sector index (.SXDP), opens new tab plunged 2.8% to its lowest level in more than three months after Trump unveiled a graduated tariff plan targeting pharmaceutical imports that could see levies on the sector jump up to 250% within 18 months. "This is where it's important to be specific about tariffs because certain stocks and sectors will be impacted differently across regions," said Steve Sosnick, chief market analyst at Interactive Brokers. "In Europe and Asia, investors are considering tariff impacts more carefully since exporters bear much of the brunt directly." The sector was also singed as Novo Nordisk ( opens new tab warned it expects continued competition from copycat versions of its Wegovy obesity drug this year, a message that sent shares of the Danish drug maker down 5.4%. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since then. Meanwhile, Swiss President Karin Keller-Sutter met with U.S. Secretary of State Marco Rubio to discuss potential trade solutions after Trump announced a 39% tariff on Swiss goods. The talks focused on increasing Swiss purchases of U.S. energy and defence products to avert the steep tariff, which threatens significant damage to Switzerland's export-driven economy. Switzerland's benchmark SMI index (.SSMI), opens new tab fell 0.9%, weighed down by drugmakers Novartis (NOVN.S), opens new tab and Roche (ROG.S), opens new tab which lost 3.3% and 2.6%, respectively. Bayer ( opens new tab shares tumbled 9.9% on investor concerns that the German pharmaceutical firm's earnings were inflated by soccer player transfer fees rather than supported by its core healthcare and agriculture businesses. On the data front, Euro zone retail sales grew quicker than thought in June, reinforcing views that the 27-nation bloc remains resilient to trade uncertainty. Among others, Beiersdorf ( opens new tab fell 8.4% and was among top decliners after the German consumer goods maker cut its annual organic sales growth outlook. On the flip side, Siemens Energy ( opens new tab rose 1% after the company said it expects to hit the upper end of its 2025 growth outlook estimates. Hiscox (HSX.L), opens new tab was the top gainer on the index, gaining 9.4% after reporting a rise in first-half insurance premiums supported by its retail business growth.
Reuters
an hour ago
- Reuters
Charles River profit forecast clouded by order cancellations from biotechs
Aug 6 (Reuters) - Charles River Laboratories' (CRL.N), opens new tab annual profit forecast raise on Wednesday was clouded by investor concerns about the higher number of order cancellations from clients, sending the contract research firm's shares down 8% in afternoon trading. The company's quarterly book-to-bill ratio – the number of orders versus those fulfilled – came in at 0.82x. Evercore ISI analyst Elizabeth Anderson said the ratio was below Wall Street expectations of 0.94x, adding some questions remain about demand environment in the sector. Charles River CEO Jim Foster said on a conference call that while proposals were higher in the quarter, cancellations from biotechs were also higher. Contract research organizations – including Charles River, Fortrea (FTRE.O), opens new tab and ICON (ICLR.O), opens new tab – have posted better-than-expected quarterly profit, reflecting a rebound in spending from pharmaceutical and biotech clients after a cautious stretch driven by tighter sector financing. Charles River's Foster, however, said that funding for smaller biotechs is still more cash constrained, due to the funding slowdown, and mid-sized biotechs are performing better, as many can support their R&D programs without external funding. "We are continuing to see clear signs that the biopharmaceutical demand is stabilizing, and in this environment, we are making gradual progress to return to organic revenue growth," he added. The Wilmington, Massachusetts-based company raised its 2025 adjusted profit forecast to $9.90 to $10.30 per share, from its previous range of $9.30 to $9.80. Charles River's overall second-quarter revenue came in at $1.03 billion, surpassing analysts' estimate of $985.1 million, according to data compiled by LSEG. On an adjusted basis, quarterly profit was $3.12 per share, above estimates of $2.50.
Reuters
an hour ago
- Reuters
Nasdaq up more than 1%, led by Apple gain
NEW YORK Aug 6 (Reuters) - U.S. stocks rose on Wednesday, led by a more than 1% gain in the Nasdaq, as Apple shares climbed after news of its plans to announce a domestic manufacturing pledge, and as the latest batch of corporate reports was upbeat. Shares of Apple (AAPL.O), opens new tab were up 5.8% and provided the biggest boost to all three of the major indexes after a White House official said the company would announce a $100-billion domestic manufacturing pledge. In addition, shares of McDonald's were up 3.6% after the fast-food restaurant's affordable menu drove global sales past expectations, while Arista Networks (ANET.N), opens new tab shares jumped 18% after the cloud networking company projected current-quarter revenue above estimates. "Earnings continue to come in better than expected," said Sam Stovall, chief investment strategist at CFRA Research. He said while there is uncertainty surrounding tariffs, investors appear to be upbeat about the near term. On Wednesday, U.S. President Donald Trump imposed an additional 25% tariff on Indian goods, citing New Delhi's continued imports of Russian oil. The Dow Jones Industrial Average (.DJI), opens new tab rose 140.32 points, or 0.32%, to 44,252.06, the S&P 500 (.SPX), opens new tab gained 49.86 points, or 0.79%, to 6,349.05 and the Nasdaq Composite (.IXIC), opens new tab added 254.12 points, or 1.22%, to 21,170.67. Also positive for stocks were increasing bets for a September rate cut. Last week's jobs report showed slowing employment growth and downward revisions for previous months. Odds for next month's rate cut stand at 93.2%, compared with just 46.7% last week, according to CME Group's FedWatch tool. Traders also bet on at least two cuts by the end of 2025. Among the day's decliners, shares of Advanced Micro Devices (AMD.O), opens new tab fell 5.4% as its data center chip revenue disappointed. Walt Disney (DIS.N), opens new tab delivered a strong quarter and lifted its full-year outlook, but its shares slipped 2%. Advancing issues outnumbered decliners by a 1.1-to-1 ratio on the New York Stock Exchange. There were 145 new highs and 65 new lows on the NYSE. On the Nasdaq, 2,057 stocks rose and 2,410 fell as declining issues outnumbered advancers by a 1.17-to-1 ratio.
